Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Tumor Growth”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableUnknownNCT01838577
What this trial is testing

Genetics of EGFR (Epidermal Growth Factor Receptor) Mutation Study

Who this might be right for
EGFR Mutation Positive Non Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC 2,000
Testing effectiveness (Phase 2)UnknownNCT04811001
What this trial is testing

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

Who this might be right for
NSCLC
Fondazione Ricerca Traslazionale 170
Early research (Phase 1)Study completedNCT01999985
What this trial is testing

Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Lung CancerNon-small Cell Lung Cancer (NSCLC)
H. Lee Moffitt Cancer Center and Research Institute 25
Early research (Phase 1)Study completedNCT02429843
What this trial is testing

TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer

Who this might be right for
Lung Cancer
University of Alabama at Birmingham 16
Early research (Phase 1)Ended earlyNCT01805908
What this trial is testing

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

Who this might be right for
Breast Cancer
Ontario Clinical Oncology Group (OCOG) 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT06702618
What this trial is testing

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Not applicableEnded earlyNCT02611310
What this trial is testing

Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 15
Testing effectiveness (Phase 2)Study completedNCT01268150
What this trial is testing

Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Who this might be right for
Locally RecurrentMetastatic Breast Cancer ( HER2 Negative)
Eisai Inc. 56
Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Early research (Phase 1)Study completedNCT02727283
What this trial is testing

A Phase 1, Randomized, Placebo-Controlled, Ascending Cohort, Dose Escalation Study in Normal Healthy Volunteers

Who this might be right for
Irritable Bowel Syndrome
GlaxoSmithKline 16
Testing effectiveness (Phase 2)Ended earlyNCT00759642
What this trial is testing

Lapatinib in Women With Metastatic Breast Cancer Who Have Failed Prior Antihormone Therapy

Who this might be right for
Metastatic Breast Cancer
University of Kansas Medical Center 33
Testing effectiveness (Phase 2)UnknownNCT00973310
What this trial is testing

Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small Cell Lung
Tianjin Medical University Cancer Institute and Hospital 50
Not applicableStudy completedNCT04179890
What this trial is testing

The Study Observes How Long Patients With Non-small Cell Lung Cancer (NSCLC) Benefit From Treatment With Epidermal Growth Factor Tyrosine Kinase Inhibitor (EGFR-TKI) When Given Either for Uncommon Mutations or for Common Mutations in the Sequence Afatinib Followed by Osimertinib

Who this might be right for
Non-squamous, Non-Small Cell Lung Cancer
Boehringer Ingelheim 462
Not applicableUnknownNCT03068013
What this trial is testing

Managing Cancer and Living Meaningfully (CALM) Adapted to Italian Cancer Care Setting

Who this might be right for
DepressionAnxietyQuality of Life
Università degli Studi di Ferrara 171
Testing effectiveness (Phase 2)Study completedNCT01897480
What this trial is testing

LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Eli Lilly and Company 168
Early research (Phase 1)Study completedNCT01741727
What this trial is testing

ABT-414 in Subjects With Solid Tumors

Who this might be right for
Squamous Cell Tumors
AbbVie (prior sponsor, Abbott) 57
Testing effectiveness (Phase 2)Looking for participantsNCT05099172
What this trial is testing

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

Who this might be right for
Advanced Non-small Cell Lung CancerEGFR MutationHER2 Mutation
Bayer 400
Testing effectiveness (Phase 2)Ended earlyNCT00402896
What this trial is testing

Malignant Pleural Effusion With ZD6474

Who this might be right for
Lung CancerPleural Effusion
M.D. Anderson Cancer Center 28
Testing effectiveness (Phase 2)Study completedNCT01885013
What this trial is testing

Myocet + Cyclophosphamide + Metformin Vs Myocet + Cyclophosphamide in 1st Line Treatment of HER2 Neg. Metastatic Breast Cancer Patients

Who this might be right for
Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 126
Not applicableUnknownNCT02801565
What this trial is testing

Clinical Observation of Recombinant Human Growth Hormone Injection Assisted IVF-ET in the Treatment of PCOS

Who this might be right for
Polycystic Ovary Syndrome
Changchun GeneScience Pharmaceutical Co., Ltd. 208
Next Page